<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515617</url>
  </required_header>
  <id_info>
    <org_study_id>CHD 045-14</org_study_id>
    <nct_id>NCT02515617</nct_id>
  </id_info>
  <brief_title>Medico-economic Study of the Subglottic Secretions Drainage in Prevention of Ventilator-associated Pneumonia (DEMETER)</brief_title>
  <acronym>DEMETER</acronym>
  <official_title>Drainage of Subglottic Secretions and Prevention of Ventilator-associated Pneumonia in Intensive carE Units: Medico-Economic Study With a Randomized clusTer and crossovER Design: DEMETER Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>URC Eco Ile de France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In France, despite the implementation of bundles to prevent Ventilator-Associated Pneumonia
      (VAP) in the last decades, the VAP incidence remains high above 10 per cent. In the last
      american recommendations of VAP prevention, the drainage of subglottic secretions (SSD) has
      been notified among the &quot;basic practices&quot; to prevent VAP. Nevertheless, the diffusion of SSD
      in ICUs remains limited. This situation is largely due to the initial overcost of the
      specific endotracheal tubes allowing SSD and to the unavailability of these devices in
      medical units in which patients are intubated before the ICU admission. So, this pragmatical
      cluster randomized and cross-over study evaluates the medico-economic impact of the
      subglottic secretions drainage in addition to VAP prevention bundles in ICU.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incremental cost-utility ratio</measure>
    <time_frame>1 year after ICU admission</time_frame>
    <description>Incremental cost to gain an extra quality-adjusted life-year (QALY) with the SSD implementation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incremental cost-effectiveness ratio</measure>
    <time_frame>1 year after ICU admission</time_frame>
    <description>Incremental cost to gain an additional patient free of adjudicated VAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental cost-utility ratio (subgroup analysis)</measure>
    <time_frame>1 year after ICU admission</time_frame>
    <description>Incremental cost to gain an extra quality-adjusted life-year (QALY) with the SSD in considering patients alive at the ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental cost-effectiveness ratio</measure>
    <time_frame>1 year after ICU admission</time_frame>
    <description>Incremental cost to gain an additional life-year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Budget impact analysis</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiologically-confirmed VAP incidence</measure>
    <time_frame>90 days after the start of invasive mechanical ventilation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiologically-confirmed VAP density of incidence</measure>
    <time_frame>90 days after the start of invasive mechanical ventilation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Defined Daily Dose of antibiotics consumption</measure>
    <time_frame>Until discharge from ICU, an expected average of 12 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-associated Conditions incidence</measure>
    <time_frame>90 days after the start of invasive mechanical ventilation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-associated Conditions density of incidence</measure>
    <time_frame>90 days after the start of invasive mechanical ventilation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection related Ventilator-associated Conditions incidence</measure>
    <time_frame>90 days after the start of invasive mechanical ventilation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of invasive mechanical ventilation</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>90 days after the start of invasive mechanical ventilation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>Until discharge from ICU, an expected average of 12 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Until discharge from hospital, an expected average of 20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>Until discharge from ICU, an expected average of 12 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-days mortality</measure>
    <time_frame>90 days after ICU admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>180-days mortality</measure>
    <time_frame>180 days after ICU admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year mortality</measure>
    <time_frame>1 year after ICU admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-extubation laryngo-tracheal dyspnea incidence</measure>
    <time_frame>Until weaning of mechanical ventilation,, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2577</enrollment>
  <condition>Ventilator-associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>Period with endotracheal tubes not allowing SSD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During this period, patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions Drainage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period with endotracheal tubes allowing SSD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During this period, patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endotracheal tubes not allowing SSD</intervention_name>
    <description>In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure</description>
    <arm_group_label>Period with endotracheal tubes not allowing SSD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endotracheal tubes allowing SSD</intervention_name>
    <description>In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.
In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours.</description>
    <arm_group_label>Period with endotracheal tubes allowing SSD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  Invasive mechanical ventilation delivered via an endotracheal tube and expected to be
             required more than 24 hours

          -  Intubation performed in units in which the specific endotracheal tube allowing the
             subglottic secretions drainage (SSD) will be available during the SSD period of the
             trial

          -  Information delivered

        Exclusion Criteria:

          -  Previous inclusion in the study

          -  Patients moribund at the ICU admission

          -  Pregnant, parturient or breast-feeding woman

          -  Patient hospitalized without consent and/or deprived of liberty by court's decision

          -  Patient under guardianship or curators

          -  Lack of social insurance

          -  Concomitant inclusion in a trial on VAP prevention

          -  Patient with no comprehension of the French language
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude LACHERADE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD VENDEE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Claude LACHERADE, MD</last_name>
    <phone>33 2 51 44 60 87</phone>
    <email>jean-claude.lacherade@chd-vendee.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU André Vésale ,</name>
      <address>
        <city>Montigny-le-Tilleul.</city>
        <zip>6110</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Piagnerelli, MD, PhD</last_name>
      <phone>32 71 92 21 25</phone>
      <email>michael.piagnerelli@chu-charleroi.be</email>
    </contact>
    <investigator>
      <last_name>Michael Piagnerelli, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Angoulème</name>
      <address>
        <city>Angoulème</city>
        <zip>16959</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Schnell, MD</last_name>
      <phone>33 5 45 24 41 5</phone>
      <email>david.schnell@ch-angouleme.fr</email>
    </contact>
    <investigator>
      <last_name>David Schnell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Annecy Genevois</name>
      <address>
        <city>Annecy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Sirodot, MD</last_name>
      <phone>33 4 50 63 63 04</phone>
      <email>msirodot@ch-annecygenevois.fr</email>
    </contact>
    <investigator>
      <last_name>Michel Sirodot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Pajot, MD</last_name>
      <phone>33 1 34 23 14 45</phone>
      <email>olivier.pajot@ch-argenteuil.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Pajot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal des Portes de l'Oise</name>
      <address>
        <city>Beaumont-sur-Oise</city>
        <zip>95260</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cedric Cleophax, MD</last_name>
      <phone>33 1 39 37 15 20</phone>
      <email>cedric.cleophax@ch-pontoise.fr</email>
    </contact>
    <investigator>
      <last_name>Cedric Cleophax, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quenot Jean-Pierre, MD, PhD</last_name>
      <email>jean-pierre.quenot@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Quenot Jean-Pierre, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendee</name>
      <address>
        <city>La roche sur yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Claude Lacherade, MD</last_name>
      <phone>33 2 51 44 60 87</phone>
      <email>jean-claude.lacherade@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Claude Lacherade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Docteur Schaffner</name>
      <address>
        <city>Lens</city>
        <zip>62307</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Thevenin, MD</last_name>
      <phone>33 3 21 69 12 34</phone>
      <email>dthevenin@ch-lens.fr</email>
    </contact>
    <investigator>
      <last_name>Didier Thevenin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier François Quesnay</name>
      <address>
        <city>Mantes la Jolie</city>
        <zip>78200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jalel Tahiri, MD</last_name>
      <email>j.tahiri@ch-mantes-la-jolie.fr</email>
    </contact>
    <investigator>
      <last_name>Jalel Tahiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU marseilles, Hôpital Nord</name>
      <address>
        <city>Marseilels</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Guervilly, MD</last_name>
      <phone>33 4 91 96 58 42</phone>
      <email>Christophe.GUERVILLY@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Laurent Papazian, MD PhD</last_name>
      <email>laurent.PAPAZIAN@ap-hm.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CH de Montauban</name>
      <address>
        <city>Montauban</city>
        <zip>82013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Bonnivard, MD</last_name>
      <email>m.bonnivard@ch-montauban.fr</email>
    </contact>
    <investigator>
      <last_name>Michel Bonnivard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cedric Bretonniere, M.D.</last_name>
      <phone>+33 2 40 08 73 63</phone>
      <email>cedric.bretonniere@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jean Reignier, MD, PhD</last_name>
      <email>jean.reignier@chu-nantes.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional d'Orléans</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Runge, MD</last_name>
      <phone>33 2 38 51 44 44</phone>
      <email>isabelle.runge@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Runge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Poissy Saint Germain</name>
      <address>
        <city>Poissy</city>
        <zip>78600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mickael Alves, MD</last_name>
      <email>malves@chi-poissy-st-germain.fr;</email>
    </contact>
    <investigator>
      <last_name>Mickael Alves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Veinstein, MD</last_name>
      <phone>33 5 49 44 43 67</phone>
      <email>Anne.VEINSTEIN@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Veinstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier René Dubos</name>
      <address>
        <city>Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cedric Cleophax, MD</last_name>
      <phone>33 1 30 75 43 40</phone>
      <email>cedric.cleophax@ch-pontoise.fr</email>
    </contact>
    <investigator>
      <last_name>Cedric Cleophax, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Delafontaine</name>
      <address>
        <city>Saint Denis</city>
        <zip>93200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Ferreira, MD</last_name>
      <phone>33 1 42 35 61 07</phone>
      <email>luisferreirav@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Luis Ferreira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Saint Nazaire</name>
      <address>
        <city>Saint Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Courouble, MD</last_name>
      <phone>33 2 72 27 80 00</phone>
      <email>p.courouble@ch-saintnazaire.fr</email>
    </contact>
    <investigator>
      <last_name>Patricia Courouble, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Etienne Herbrecht, MD</last_name>
      <phone>33 3 88 12 79 13</phone>
      <email>jean-etienne.herbrecht@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Etienne Herbrecht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferhat Mezziani, MD, PhD</last_name>
      <phone>33 3 88 11 67 68</phone>
      <email>ferhat.meziani@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Ferhat Mezziani, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours, site Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Garot, MD</last_name>
      <phone>33 2 47 47 38 55</phone>
      <email>garot@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Denis Garot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours, site Trousseau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Cohen, MD</last_name>
      <email>b.cohen@chu-tours.fr;</email>
    </contact>
    <investigator>
      <last_name>Benjamin Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pointe à Pitre les Abymes</name>
      <address>
        <city>Pointe-à-Pitre</city>
        <zip>97159</zip>
        <country>Guadeloupe</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Valette, MD, PhD</last_name>
      <email>marc.valette@chu-guadeloupe.fr;</email>
    </contact>
    <investigator>
      <last_name>Marc Valette, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Réunion, site de Saint Pierre de la Réunion</name>
      <address>
        <city>Saint Pierre</city>
        <zip>97448</zip>
        <country>Réunion</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gil Mourembles, MD</last_name>
      <phone>33 262 35 90 70</phone>
      <email>gil.mourembles@chu-reunion.fr</email>
    </contact>
    <investigator>
      <last_name>Gil Mourembles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Réunion, site de Saint Pierre de la Réunion</name>
      <address>
        <city>Saint Pierre</city>
        <zip>97448</zip>
        <country>Réunion</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Couret, MD</last_name>
      <phone>33 2 62 35 90 00</phone>
      <email>david.couret@chu-reunion.fr</email>
    </contact>
    <investigator>
      <last_name>David Couret, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Réunion, site de Saint Denis de la Réunion</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97405</zip>
        <country>Réunion</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Martinet, MD</last_name>
      <email>olivier.martinet@chu-reunion.fr;</email>
    </contact>
    <investigator>
      <last_name>Martinet Olivier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Guadeloupe</country>
    <country>Réunion</country>
  </location_countries>
  <reference>
    <citation>Muscedere J, Rewa O, McKechnie K, Jiang X, Laporta D, Heyland DK. Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: a systematic review and meta-analysis. Crit Care Med. 2011 Aug;39(8):1985-91. doi: 10.1097/CCM.0b013e318218a4d9. Review.</citation>
    <PMID>21478738</PMID>
  </reference>
  <reference>
    <citation>Lacherade JC, De Jonghe B, Guezennec P, Debbat K, Hayon J, Monsel A, Fangio P, Appere de Vecchi C, Ramaut C, Outin H, Bastuji-Garin S. Intermittent subglottic secretion drainage and ventilator-associated pneumonia: a multicenter trial. Am J Respir Crit Care Med. 2010 Oct 1;182(7):910-7. doi: 10.1164/rccm.200906-0838OC. Epub 2010 Jun 3.</citation>
    <PMID>20522796</PMID>
  </reference>
  <reference>
    <citation>Klompas M, Branson R, Eichenwald EC, Greene LR, Howell MD, Lee G, Magill SS, Maragakis LL, Priebe GP, Speck K, Yokoe DS, Berenholtz SM. Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014 Sep;35 Suppl 2:S133-54.</citation>
    <PMID>25376073</PMID>
  </reference>
  <reference>
    <citation>Branch-Elliman W, Wright SB, Howell MD. Determining the Ideal Strategy for Ventilator-associated Pneumonia Prevention. Cost-Benefit Analysis. Am J Respir Crit Care Med. 2015 Jul 1;192(1):57-63. doi: 10.1164/rccm.201412-2316OC.</citation>
    <PMID>25871807</PMID>
  </reference>
  <reference>
    <citation>Loupec T, Petitpas F, Kalfon P, Mimoz O. Subglottic secretion drainage in prevention of ventilator-associated pneumonia: mind the gap between studies and reality. Crit Care. 2013 Dec 9;17(6):R286. doi: 10.1186/cc13149.</citation>
    <PMID>24321315</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2015</study_first_submitted>
  <study_first_submitted_qc>August 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2015</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ventilator-associated pneumonia</keyword>
  <keyword>Subglottic-secretions drainage</keyword>
  <keyword>Critically ill patients</keyword>
  <keyword>Cost-utility analysis</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

